Immunomedics data point to Trodelvy’s $21B potential

New data from Immunomedics suggest its antibody-drug conjugate Trodelvy is on track for the label expansions worked into Gilead’s $21 billion takeout price for the biotech. At the European Society for Clinical Oncology Virtual Congress, the company shared a pair of posters that provide confirmatory data for Trodelvy in triple-negative breast cancer following its conditional approval in April, and make the case for an expansion into urothelial carcinoma. 

The results came amid a flood of data presented this weekend at ESMO, including several readouts on next generation bispecific antibodies from  Amgen Inc. (NYSE:AMGN) and Johnson & Johnson (NYSE:JNJ) as well as evidence that blockbusters from AstraZeneca plc (LSE:AZN; NYSE:AZN) and Bristol Myers Squibb Co. (NYSE:BMS) may be effective in new lines of treatment and combinations...